[go: up one dir, main page]

MX2020007945A - Proteinas f del rsv estabilizadas y usos de las mismas. - Google Patents

Proteinas f del rsv estabilizadas y usos de las mismas.

Info

Publication number
MX2020007945A
MX2020007945A MX2020007945A MX2020007945A MX2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A MX 2020007945 A MX2020007945 A MX 2020007945A
Authority
MX
Mexico
Prior art keywords
proteins
rsv
stabilized rsv
stabilized
immunogenic compositions
Prior art date
Application number
MX2020007945A
Other languages
English (en)
Inventor
Andrew Bett
Lan Zhang
Arthur Fridman
Eberhard Durr
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020007945A publication Critical patent/MX2020007945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación se refiere a proteínas F del RSV y composiciones inmunógenas que contienen las mismas, así como métodos de uso de las composiciones inmunógenas y composiciones que comprenden las proteínas F del RSV.
MX2020007945A 2018-01-29 2019-01-24 Proteinas f del rsv estabilizadas y usos de las mismas. MX2020007945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623184P 2018-01-29 2018-01-29
PCT/US2019/014873 WO2019147749A2 (en) 2018-01-29 2019-01-24 Stabilized rsv f proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020007945A true MX2020007945A (es) 2020-09-24

Family

ID=67396243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007945A MX2020007945A (es) 2018-01-29 2019-01-24 Proteinas f del rsv estabilizadas y usos de las mismas.

Country Status (11)

Country Link
US (2) US11566051B2 (es)
EP (1) EP3746462A4 (es)
JP (1) JP7541482B2 (es)
KR (1) KR102809623B1 (es)
CN (1) CN111655715A (es)
AU (1) AU2019212237B2 (es)
BR (1) BR112020015308A8 (es)
CA (1) CA3088546A1 (es)
MA (1) MA51230A (es)
MX (1) MX2020007945A (es)
WO (1) WO2019147749A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
BR112022024248A2 (pt) * 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
MX2023006056A (es) 2020-11-25 2023-06-06 Akagera Medicines Inc Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
WO2022169835A1 (en) * 2021-02-03 2022-08-11 The Board Of Trustees Of The University Of Illinois Vaccine and methods for preventing filariasis and dirofilariasis
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
KR20250031230A (ko) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
AR132981A1 (es) * 2023-06-16 2025-08-13 Glaxosmithkline Biologicals Sa Proteínas rsv-f sustituidas con cisteína
CN119490569A (zh) * 2023-08-16 2025-02-21 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用
WO2025052180A2 (en) * 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN118496324B (zh) * 2024-05-22 2025-10-21 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN118406159B (zh) * 2024-05-22 2025-07-08 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1587816B1 (en) 2002-12-23 2010-06-16 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7803397B2 (en) 2003-09-15 2010-09-28 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1766094A4 (en) 2004-05-18 2009-11-25 Vical Inc FLUID VIRUS VACCINE COMPOSITION AND USE METHOD
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
BRPI1010692A2 (pt) 2009-06-17 2016-03-15 Sharp Kk "circuito de acionamento de exibição, dispositivo de exibição e método de acionamento de exibição"
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
KR101762466B1 (ko) 2009-12-23 2017-07-27 노파르티스 아게 지질, 지질 조성물 및 이의 사용 방법
AU2011305617A1 (en) 2010-09-20 2013-02-21 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
KR102032002B1 (ko) 2011-11-23 2019-10-14 머크 샤프 앤드 돔 코포레이션 알루미늄 히드록시포스페이트 아주반트의 제조 방법
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US10821175B2 (en) * 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
WO2017070620A2 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
PT3393512T (pt) * 2015-12-23 2026-01-16 Pfizer Inc Mutantes de proteína f de rsv
CA3015570A1 (en) 2016-03-29 2017-10-05 Peter Kwong Substitutions-modified prefusion rsv f proteins and their use

Also Published As

Publication number Publication date
AU2019212237A1 (en) 2020-07-30
BR112020015308A8 (pt) 2023-02-07
US12234265B2 (en) 2025-02-25
MA51230A (fr) 2021-05-05
WO2019147749A3 (en) 2019-09-19
AU2019212237B2 (en) 2024-12-12
RU2020128445A3 (es) 2022-02-28
BR112020015308A2 (pt) 2020-12-08
US20210300971A1 (en) 2021-09-30
KR20200115567A (ko) 2020-10-07
EP3746462A2 (en) 2020-12-09
KR102809623B1 (ko) 2025-05-16
EP3746462A4 (en) 2022-01-05
CN111655715A (zh) 2020-09-11
US11566051B2 (en) 2023-01-31
CA3088546A1 (en) 2019-08-01
RU2020128445A (ru) 2022-02-28
JP2021511356A (ja) 2021-05-06
US20230141153A1 (en) 2023-05-11
WO2019147749A2 (en) 2019-08-01
JP7541482B2 (ja) 2024-08-28

Similar Documents

Publication Publication Date Title
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12019501557A1 (en) Bacillus isolates and uses thereof
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MY193249A (en) Anti-human cd19 antibodies with high affinity
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
NZ760847A (en) Purified 2,5-furandicarboxylic acid pathway products
MY191081A (en) Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
MY192425A (en) Polymorphs
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
PH12021551100A1 (en) Dried biological compositions and methods thereof
MY201431A (en) Polyether derivatives, uses, and methods of making the same
ZA202005325B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
MY202820A (en) Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений